Exploring the Prognostic and chemotherapy Response Potential of CDR1as, circRNA-000284, and circ-ITCH as Circulating Biomarkers in Breast Cancer

Saba  Mirzae; Mahdieh  Salimi; Hossein  Mozdarani

doi:10.18502/bccr.v15i4.18749

Saba Mirzae Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
Mahdieh Salimi Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
Hossein Mozdarani Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

DOI: https://doi.org/10.18502/bccr.v15i4.18749

Keywords: Breast cancer, circRNAs, Biomarkers, Chemotherapy, Prognosis

Abstract

Background: Breast cancer is the leading cause of death for women worldwide. Op- timal methods for most cancer control require the use of appropriate biomarkers. Re- cently, circular RNAs (circRNAs), as closed-loop RNA molecules generated through reverse splicing, have emerged as promising biomarkers for cancer development.

Methods: In this observation, the expression of 3 unique circRNAs - cdr1as, circR- NA-000284, circ-ITCH - within the peripheral blood of breast cancer patients was studied using Real-Time RT-PCR before and after chemotherapy compared with the control.

Results: The data confirmed that the analyzed circRNAs expression was significantly altered in breast cancer patients compared to the controls (p< 0.0001). These altera- tions have been related to advanced stages, lymph node involvement, and metastasis. CircRNA-000284 expression considerably decreased after chemotherapy (p< 0.0001). This may propose its potential as a biomarker for monitoring treatment response.

Conclusion: Data suggests that increased expression of circRNA-cdr1as and circR- NA-000284, along with decreased expression of circ-ITCH, are observed in breast can- cer patients. These expression changes are associated with poor prognosis and predic- tion. Additionally, the expression level of circRNA-000284 significantly decreases after chemotherapy, indicating its potential as a candidate marker for studying chemother- apy response. these findings provide valuable insights for the development of novel strategies in the management and treatment of breast cancer. However, further studies are required to validate the clinical utility of these circRNAs as biomarkers and to ex- plore their underlying mechanisms in breast cancer progression